Munich-based startup Leon Nanodrugs has completed an oversubscribed funding round of undisclosed amount. According to the company, both existing and new investors participated.
With the capital, Leon Nanodrugs plans to advance the market launch of its nano-systems. At the same time, the company is planning the transition from the advanced development phase to full commercial deployment. Furthermore, international distribution is to be expanded to serve pharmaceutical and biotechnology companies worldwide. With this, the biotech startup aims to strengthen its position as a technology provider for the industrial production of lipid nanoparticles.
Production of lipid nanoparticles in focus
Leon Nanodrugs develops systems for manufacturing lipid nanoparticles, or LNP for short. These particles serve as transport shells for active ingredients. They deliver RNA molecules into cells and are thus a foundation for RNA-based medicines, cancer vaccines, as well as cell and gene therapies.
Such therapies often emerge in small batches. At the same time, strict regulatory requirements apply. Production must be reproducible and meet defined quality standards. Additionally, many development programs require short lead times, even at later commercial scales.
Leon Nanodrugs addresses these requirements with a platform designed to enable consistent manufacturing from early development through commercial production. According to the company, the manufacturing process can be transferred from laboratory to production scale without requiring fundamental adaptation. With this, Leon Nanodrugs aims to advance scalable production of lipid nanoparticles and strengthen manufacturing expertise in Munich’s biotechnology ecosystem.
Proprietary mixing technology at the core
The central element of the platform is the company’s proprietary FR-JET technology. This is a special mixing process for manufacturing nanoparticles. The process is designed to allow robust scaling while ensuring consistent product quality. According to the company, this reduces operational risk when transitioning development projects into commercial manufacturing.
Christian Nafe, Chief Financial Officer of Leon Nanodrugs, says:
“This funding gives us the momentum we need to expand our commercial presence, support our partners worldwide, and advance the further development of a production platform for the next generation of therapeutics.”
Support also comes from the investor side. Frank Mühlenbeck, managing partner at LBBW Venture Capital and chairman of the supervisory board of Leon Nanodrugs, explains:
“With market-ready systems, a differentiated technology platform, and growing customer demand, we believe Leon Nanodrugs is well positioned to establish itself as a leading company in scalable nanoparticle manufacturing.”
For the Munich startup, the involvement of experienced investors underscores the ambition to scale its proprietary technology to industrial level and position itself in international competition.
